Is a 10% azelaic acid formulation appropriate for patients with skin of color (e.g., for mild acne or early post‑inflammatory hyperpigmentation)?

10% Azelaic Acid in Skin of Color

Yes, 10% azelaic acid is appropriate for patients with skin of color, particularly for mild acne and post-inflammatory hyperpigmentation, though the standard FDA-approved concentration is 20% for acne and 15% for other indications. 1

Primary Recommendation Based on Guidelines

The American Academy of Dermatology explicitly recommends azelaic acid for patients with Fitzpatrick skin types IV or greater because of its lightening effect on dyspigmentation, making it particularly valuable in skin of color. 1 Specifically:

• Azelaic acid is recommended as a useful adjunctive acne treatment specifically for postinflammatory dyspigmentation. 1
• The agent has documented use in patients with sensitive skin or darker skin types due to its dual action on both acne and hyperpigmentation. 1
• Azelaic acid is pregnancy category B, making it safer than many alternatives. 1

Evidence for Lower Concentrations (10%)

While FDA-approved formulations are 15-20%, emerging evidence supports 10% formulations:

• A 2021 randomized controlled trial demonstrated that 10% azelaic acid nanocrystal hydrogel achieved a 36.51% success rate with significant reductions in both inflammatory (39.15%) and non-inflammatory lesions (34.58%) at 8 weeks. 2
• This 10% formulation showed comparable or superior efficacy to standard 20% cream with a low adverse event rate. 2
• The lower concentration may offer improved tolerability while maintaining therapeutic benefit. 2

Specific Benefits in Skin of Color

Azelaic acid addresses both acne and the subsequent post-inflammatory hyperpigmentation that disproportionately affects darker skin types: 3, 4

• A 1998 study in phototypes IV-VI demonstrated significant decreases in pigmentary intensity compared to vehicle (p=0.021 by investigator assessment, p=0.039 by chromometer). 5
• 15% azelaic acid gel specifically reduced post-inflammatory hyperpigmentation in acne patients, with patients reporting much smoother skin and high satisfaction rates. 4
• Recent 2024 data showed 15% azelaic acid gel effectively improved both post-inflammatory erythema and hyperpigmentation with minimal adverse effects on skin barrier function. 6

Mechanism Supporting Use in Darker Skin

Azelaic acid works through multiple complementary mechanisms: 1, 7

• Comedolytic action (normalizes keratinization)
• Antibacterial activity against P. acnes and S. epidermidis
• Anti-inflammatory effects
• Antimelanogenic properties (inhibits tyrosinase, reducing hyperpigmentation)

Safety Profile

The FDA label specifically warns to monitor patients with dark complexions for early signs of hypopigmentation, though isolated reports are rare. 7 However:

• Clinical studies in darker-skinned patients (phototypes IV-VI) demonstrated good tolerability with only mild, transient burning and stinging. 5
• Adverse events are typically mild: pruritus, burning, stinging, tingling, erythema, dryness. 1
• Azelaic acid produced slightly more burning at weeks 4 and 12 compared to vehicle, but patients rated satisfaction highly. 5

Practical Application Algorithm

For mild acne with or without early PIH in skin of color:

1. Start with 10-15% azelaic acid applied twice daily (morning and evening) to affected areas. 1, 2
2. Combine with topical retinoids for optimal comedonal and inflammatory acne control, as retinoids are the core of topical therapy. 1
3. Add benzoyl peroxide if bacterial resistance is a concern or for moderate inflammatory acne. 1
4. Monitor at 4-week intervals for both therapeutic response and any signs of hypopigmentation (though rare). 7, 5
5. Continue for 12-24 weeks for full effect on both acne and hyperpigmentation. 6, 5, 4

Important Caveats

• While 10% formulations show promise in recent research, FDA-approved concentrations remain 15% gel and 20% cream. 1
• Azelaic acid is only mildly effective as monotherapy; combination with retinoids or other agents is typically necessary for optimal acne control. 1
• The lightening effect is therapeutic for PIH but requires monitoring to avoid unwanted hypopigmentation in darker skin. 7
• Safety and effectiveness in pediatric patients <12 years have not been established. 1
• Percutaneous absorption is minimal (~4% systemically absorbed), with negligible impact on endogenous plasma levels. 7